Epidemiology of Melanoma in Spain: Estimation of Number of Patients With Stage III Disease Eligible for Adjuvant Therapies E. Nagore, D. Moreno-Ramírez, P. Ortiz-Romero, E. Martín-Sánchez, A. Martínez-Fernández, S. Puig

Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management S.J.E. Hwang, R. Anforth, G. Carlos, P. Fernandez-Peñas

RF – Can Targeted Therapy Be Combined With Immunotherapy for Melanoma? N. Mohino-Farré, A. Boada-García